Inventor · disambiguated record
Christophe Meille
Also filed as: MEILLE CHRISTOPHE
2 granted patents·11 pending applications·3 citations·filing 2016–2021
46Inventor score
Files withNOVARTIS AG13
Top patents by PatentIndex Score
13 records- 0169US10966978B2Dose and regimen for HDM2-p53 interaction inhibitorsNOVARTIS AG·Filed 2017·Granted Apr 6, 2021·2 cites·20 claims
- 0269US10935540B2GDF-15 as a haematological toxicity biomarkerNOVARTIS AG·Filed 2016·Granted Mar 2, 2021·1 cites·14 claims
- 0362US2021255166A1Gdf-15 as a haematological toxicity biomarkerNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0460US2021386763A1Pharmaceutical combinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 0560US2022281970A1Pharmaceutical CombinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 0659US2025041296A1Novel dosing regimens for mdm2 inhibitorsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 0757US2021247383A1Gdf-15 as a haematological toxicity biomarkerNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0856US2022031697A1Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumorsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0952US2023293529A1Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disordersNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1046US2020281925A1Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumorsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1144US2022331318A1Use of an mdm2 inhibitor for the treatment of myelofibrosisNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1243US2021363254A1Pharmaceutical combinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1343US2023172920A1Dosing regimen for treating a disease modulated by csf-1rNOVARTIS AG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christophe Meille files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →